{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:30:01Z","timestamp":1791563401492,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018372","name":"Pfizer Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018372","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s13555-024-01244-7","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:17:42Z","timestamp":1722889062000},"page":"2479-2493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Quality of Life and Burden of Moderate-to-Severe Atopic Dermatitis in Adult Patients Within the Asia\u2013Pacific Region: A Cross-sectional Survey"],"prefix":"10.1007","volume":"14","author":[{"given":"Chia-Yu","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriwan","family":"Wananukul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha Suyien","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wook","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Fang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9193-9844","authenticated-orcid":false,"given":"Sean","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6929-665X","authenticated-orcid":false,"given":"Qi Qing","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-8172","authenticated-orcid":false,"given":"See-Hwee","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2874-1786","authenticated-orcid":false,"given":"Sophie Bozhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"issue":"2","key":"1244_CR1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","volume":"70","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1244_CR2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","volume":"123","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144\u201351.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1244_CR3","unstructured":"Kolb L, Ferrer-Bruker SJ. Atopic dermatitis. StatPearls\u2013NCBI Bookshelf [Internet]. Treasure Island (FL): StatPearls:."},{"issue":"12","key":"1244_CR4","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s13555-022-00819-6","volume":"12","author":"AN Fasseeh","year":"2022","unstructured":"Fasseeh AN, Elezbawy B, Korra N, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther. 2022;12(12):2653\u201368.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1244_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"1244_CR6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/all.12619","volume":"70","author":"C Mortz","year":"2015","unstructured":"Mortz C, Andersen K, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy. 2015;70(7):836\u201345.","journal-title":"Allergy"},{"issue":"4","key":"1244_CR7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s13555-019-00332-3","volume":"9","author":"YI Lopez Carrera","year":"2019","unstructured":"Lopez Carrera YI, Al Hammadi A, Huang YH, Llamado LJ, Mahgoub E, Tallman AM. Epidemiology, diagnosis, and treatment of atopic dermatitis in the developing countries of Asia, Africa, Latin America, and the Middle East: a review. Dermatol Ther (Heidelb). 2019;9(4):685\u2013705.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1244_CR8","doi-asserted-by":"crossref","unstructured":"Yong AM-Y, Tay Y-K. Atopic dermatitis: racial and ethnic differences. Dermatol Clin. 2017;35(3):395\u2013402.","DOI":"10.1016\/j.det.2017.02.012"},{"issue":"1","key":"1244_CR9","first-page":"2","volume":"2","author":"PA Gross","year":"1987","unstructured":"Gross PA. Epidemiology of hospital-acquired pneumonia. Semin Respir Infect. 1987;2(1):2\u20137.","journal-title":"Semin Respir Infect"},{"issue":"4","key":"1244_CR10","doi-asserted-by":"crossref","DOI":"10.1002\/ski2.62","volume":"2","author":"P Heim-Ohmayer","year":"2022","unstructured":"Heim-Ohmayer P, Freiberger A, Gedik M, et al. The impact of stigmatization of psoriasis, atopic dermatitis and mastocytosis in different areas of life\u2014a qualitative interview study. Skin Health Dis. 2022;2(4):e62.","journal-title":"Skin Health Dis"},{"key":"1244_CR11","doi-asserted-by":"crossref","unstructured":"Gochnauer H, Valdes-Rodriguez R, Cardwell L, Anolik RB. The psychosocial impact of atopic dermatitis. In: Feldman SR, Strowd LC, Lovell KK, editors. Management of atopic dermatitis: methods and challenges. Cham: Springer; 2017. p. 57\u201369.","DOI":"10.1007\/978-3-319-64804-0_6"},{"issue":"6","key":"1244_CR12","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jaci.2013.12.1079","volume":"133","author":"TS Tang","year":"2014","unstructured":"Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol. 2014;133(6):1615\u201325.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1244_CR13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/1346-8138.14218","volume":"45","author":"K Arima","year":"2018","unstructured":"Arima K, Gupta S, Gadkari A, et al. Burden of atopic dermatitis in Japanese adults: analysis of data from the 2013 National Health and Wellness Survey. J Dermatol. 2018;45(4):390\u20136.","journal-title":"J Dermatol"},{"issue":"7","key":"1244_CR14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/1346-8138.15366","volume":"47","author":"H Murota","year":"2020","unstructured":"Murota H, Inoue S, Yoshida K, Ishimoto A. Cost of illness study for adult atopic dermatitis in Japan: a cross-sectional Web-based survey. J Dermatol. 2020;47(7):689\u201398.","journal-title":"J Dermatol"},{"issue":"1","key":"1244_CR15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13555-020-00459-8","volume":"11","author":"G Girolomoni","year":"2021","unstructured":"Girolomoni G, Luger T, Nosbaum A, et al. The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey. Dermatol Ther (Heidelb). 2021;11(1):117\u201330.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1244_CR16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaad.2019.03.037","volume":"81","author":"L Eckert","year":"2019","unstructured":"Eckert L, Gupta S, Gadkari A, Mahajan P, Gelfand JM. Burden of illness in adults with atopic dermatitis: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019;81(1):187\u201395.","journal-title":"J Am Acad Dermatol"},{"issue":"9030","key":"1244_CR17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(05)65206-3","volume":"348","author":"MJ Rothe","year":"1996","unstructured":"Rothe MJ, Grant-Kels JM. Diagnostic criteria for atopic dermatitis. Lancet. 1996;348(9030):769\u201370.","journal-title":"Lancet"},{"issue":"1","key":"1244_CR18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s41687-019-0128-z","volume":"3","author":"L Newton","year":"2019","unstructured":"Newton L, DeLozier AM, Griffiths PC, et al. Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. J Patient Rep Outcomes. 2019;3(1):42.","journal-title":"J Patient Rep Outcomes"},{"issue":"Suppl 2","key":"1244_CR19","first-page":"A97","volume":"76","author":"K Rhatigan","year":"2021","unstructured":"Rhatigan K, Tsami K, Kesavan H, Turner R, Jolley C, Hull J et al. P57\u2005Patient global impression of severity scale characterises symptom severity in chronic cough. Thorax. 2021;76(Suppl 2):A97-A8.","journal-title":"Thorax"},{"key":"1244_CR20","unstructured":"The University of Nottingham. POWM - Patient Oriented Eczema Measure. https:\/\/www.nottingham.ac.uk\/research\/groups\/cebd\/resources\/poem.aspx. Accessed 17 Nov 2023."},{"issue":"3","key":"1244_CR21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan G. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1244_CR22","first-page":"997","volume":"159","author":"M Basra","year":"2008","unstructured":"Basra M, Fenech R, Gatt R, Salek M, Finlay AY. The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997\u20131035.","journal-title":"Br J Dermatol"},{"key":"1244_CR23","unstructured":"EQ-5D EuroQol. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/. Accessed 17 Nov 2023."},{"key":"1244_CR24","unstructured":"Dermatology Life Quality Index Cardiff University. https:\/\/www.cardiff.ac.uk\/medicine\/resources\/quality-of-life-questionnaires\/dermatology-life-quality-index. Accessed 17 Nov 2023."},{"key":"1244_CR25","unstructured":"WPAI Scoring Reilly Associates. http:\/\/www.reillyassociates.net\/WPAI_Scoring.html. Accessed 17 Nov 2023."},{"issue":"9","key":"1244_CR26","doi-asserted-by":"crossref","first-page":"adv00556","DOI":"10.2340\/00015555-3918","volume":"101","author":"TC Chan","year":"2021","unstructured":"Chan TC, Lin YC, Cho YT, Tang CH, Chu CY. Impact of Atopic Dermatitis on Work and Activity Impairment in Taiwan. Acta Derm Venereol. 2021;101(9):adv00556.","journal-title":"Acta Derm Venereol"},{"key":"1244_CR27","unstructured":"BOXPLOT Statement SAS Help Center. https:\/\/documentation.sas.com\/doc\/en\/pgmsascdc\/9.4_3.5\/grstatgraph\/p0vuh82v39fsasn1vqhzmhdl8y16.htm. Accessed 17 Nov 2023."},{"issue":"10","key":"1244_CR28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/psb.1505","volume":"27","author":"S Chaplin","year":"2016","unstructured":"Chaplin S. Guide to treatments used for atopic dermatitis in adults. Prescriber. 2016;27(10):30\u20139.","journal-title":"Prescriber"},{"issue":"11","key":"1244_CR29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029047","volume":"96","author":"X Wang","year":"2017","unstructured":"Wang X, Shi XD, Li LF, Zhou P, Shen YW, Song QK. Prevalence and clinical features of adult atopic dermatitis in tertiary hospitals of China. Medicine (Baltimore). 2017;96(11): e6317.","journal-title":"Medicine (Baltimore)"},{"key":"1244_CR30","unstructured":"Upham B. 10 things to know about eczema (atopic dermatitis) on the face and neck October 2022. https:\/\/www.everydayhealth.com\/eczema\/things-to-know-about-eczema-on-the-face-and-neck\/. Accessed 17 Nov 2023."},{"issue":"3","key":"1244_CR31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.alit.2020.02.006","volume":"69","author":"N Katoh","year":"2020","unstructured":"Katoh N, Ohya Y, Ikeda M, et al. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020;69(3):356\u201369.","journal-title":"Allergol Int"},{"issue":"10","key":"1244_CR32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.47102\/annals-acadmedsg.V45N10p439","volume":"45","author":"YK Tay","year":"2016","unstructured":"Tay YK, Chan YC, Chandran NS, et al. Guidelines for the management of atopic dermatitis in Singapore. Ann Acad Med Singap. 2016;45(10):439\u201350.","journal-title":"Ann Acad Med Singap"},{"issue":"4","key":"1244_CR33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jmii.2022.03.004","volume":"55","author":"T-C Yao","year":"2022","unstructured":"Yao T-C, Wang I-J, Sun H-L, et al. Taiwan guidelines for the diagnosis and management of pediatric atopic dermatitis: consensus statement of the Taiwan Academy of Pediatric Allergy, Asthma and Immunology. J Microbiol Immunol Infect. 2022;55(4):561\u201372.","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"1244_CR34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.5021\/ad.2015.27.5.563","volume":"27","author":"JE Kim","year":"2015","unstructured":"Kim JE, Kim HJ, Lew BL, et al. Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): general management and topical treatment. Ann Dermatol. 2015;27(5):563\u201377.","journal-title":"Ann Dermatol"},{"issue":"3","key":"1244_CR35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/1346-8138.12065","volume":"40","author":"D Rubel","year":"2013","unstructured":"Rubel D, Thirumoorthy T, Soebaryo RW, et al. Consensus guidelines for the management of atopic dermatitis: an Asia\u2013Pacific perspective. J Dermatol. 2013;40(3):160\u201371.","journal-title":"J Dermatol"},{"issue":"8","key":"1244_CR36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1468-3083.2012.04635.x","volume":"26","author":"J Ring","year":"2012","unstructured":"Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1244_CR37","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1468-3083.2012.04636.x","volume":"26","author":"J Ring","year":"2012","unstructured":"Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1244_CR38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/pde.13678","volume":"36","author":"LM LePoidevin","year":"2019","unstructured":"LePoidevin LM, Lee DE, Shi VY. A comparison of international management guidelines for atopic dermatitis. Pediatr Dermatol. 2019;36(1):36\u201365.","journal-title":"Pediatr Dermatol"},{"issue":"12","key":"1244_CR39","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.15090","volume":"46","author":"N Katoh","year":"2019","unstructured":"Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46(12):1053\u2013101.","journal-title":"J Dermatol"},{"issue":"4","key":"1244_CR40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/1744666X.2017.1292134","volume":"13","author":"M Kraft","year":"2017","unstructured":"Kraft M, Worm M. Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Rev Clin Immunol. 2017;13(4):301\u201310.","journal-title":"Expert Rev Clin Immunol"},{"key":"1244_CR41","unstructured":"Prescription Oral: National Eczema Association; 2023. https:\/\/nationaleczema.org\/eczema\/treatment\/immunosuppressants\/#:~:text=Immunosuppressants%20are%20prescribed%20for%20moderate,the%20risk%20of%20skin%20infection. Accessed 17 Nov 2023."},{"issue":"6","key":"1244_CR42","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jaad.2022.01.009","volume":"86","author":"DM Davis","year":"2022","unstructured":"Davis DM, Drucker AM, Alikhan A, et al. American Academy of Dermatology Guidelines: awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol. 2022;86(6):1335\u20136.e18.","journal-title":"J Am Acad Dermatol"},{"issue":"92","key":"1244_CR43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","volume":"60","author":"JM Hanifin","year":"1980","unstructured":"Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;60(92):44\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1244_CR44","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2133.1994.tb08532.x","volume":"131","author":"H Williams","year":"1994","unstructured":"Williams H, Jburney P, Pembroke A, Hay R, Party ADDCW. The UK Working Party\u2019s diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131(3):406\u201316.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1244_CR45","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2016.08.047","volume":"76","author":"YM Andersen","year":"2017","unstructured":"Andersen YM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol. 2017;76(2):274\u201380e1.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1244_CR46","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol. 2018;121(5):604\u201312e.3.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1244_CR47","doi-asserted-by":"crossref","unstructured":"Loiselle AR, Thibau IJ, Johnson JK, Guadalupe M, Begolka WS. Financial and treatment access burden associated with atopic dermatitis comorbidities. Ann Allergy Asthma Immunol. 2024;132(2):243\u20135.","DOI":"10.1016\/j.anai.2023.10.015"},{"issue":"5","key":"1244_CR48","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00403-021-02246-7","volume":"314","author":"J Huang","year":"2022","unstructured":"Huang J, Choo YJ, Smith HE, Apfelbacher C. Quality of life in atopic dermatitis in Asian countries: a systematic review. Arch Dermatol Res. 2022;314(5):445\u201362.","journal-title":"Arch Dermatol Res"},{"issue":"21","key":"1244_CR49","doi-asserted-by":"crossref","first-page":"11593","DOI":"10.3390\/ijerph182111593","volume":"18","author":"A Nagata","year":"2021","unstructured":"Nagata A, Kazi T, Akter Z, et al. The influence of atopic dermatitis on health-related quality of life in Bangladesh. Int J Environ Res Public Health. 2021;18(21):11593.","journal-title":"Int J Environ Res Public Health"},{"issue":"10","key":"1244_CR50","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/1346-8138.16054","volume":"48","author":"K Kamei","year":"2021","unstructured":"Kamei K, Hirose T, Yoshii N, Tanaka A. Burden of illness, medication adherence, and unmet medical needs in Japanese patients with atopic dermatitis: a retrospective analysis of a cross-sectional questionnaire survey. J Dermatol. 2021;48(10):1491\u20138.","journal-title":"J Dermatol"},{"issue":"4","key":"1244_CR51","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/1346-8138.14787","volume":"46","author":"N Katoh","year":"2019","unstructured":"Katoh N, Saeki H, Kataoka Y, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): baseline characteristics, treatment history and disease burden. J Dermatol. 2019;46(4):290\u2013300.","journal-title":"J Dermatol"},{"issue":"6S1","key":"1244_CR52","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1097\/DER.0000000000000908","volume":"33","author":"K Koszor\u00fa","year":"2022","unstructured":"Koszor\u00fa K, Hajdu K, Brodszky V, et al. General and skin-specific health-related quality of life in patients with atopic dermatitis before and during the COVID-19 pandemic. Dermatitis. 2022;33(6S1):S92\u2013103.","journal-title":"Dermatitis"},{"key":"1244_CR53","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s11136-020-02499-1","volume":"29","author":"AW Vilsb\u00f8ll","year":"2020","unstructured":"Vilsb\u00f8ll AW, Kragh N, Hahn-Pedersen J, Jensen CE. Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study. Qual Life Res. 2020;29:2529\u201339.","journal-title":"Qual Life Res"},{"issue":"4","key":"1244_CR54","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1111\/ijd.14763","volume":"59","author":"G Birdi","year":"2020","unstructured":"Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020;59(4):e75\u201391.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1244_CR55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2340\/00015555-2797","volume":"98","author":"SH Lee","year":"2018","unstructured":"Lee SH, Lee SH, Lee SY, Lee B, Lee S-H, Park YL. Psychological health status and health-related quality of life in adults with atopic dermatitis: a nationwide cross-sectional study in South Korea. Acta Derm Venereol. 2018;98(1):89\u201397.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1244_CR56","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.apnu.2017.06.001","volume":"31","author":"Y Kwak","year":"2017","unstructured":"Kwak Y, Kim Y. Health-related quality of life and mental health of adults with atopic dermatitis. Arch Psychiatr Nurs. 2017;31(5):516\u201321.","journal-title":"Arch Psychiatr Nurs"},{"issue":"1","key":"1244_CR57","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1186\/s12913-023-09840-7","volume":"23","author":"Z Beretzky","year":"2023","unstructured":"Beretzky Z, Koszor\u00fa K, Rencz F, et al. Societal costs and health related quality of life in adult atopic dermatitis. BMC Health Serv Res. 2023;23(1):859.","journal-title":"BMC Health Serv Res"},{"key":"1244_CR58","doi-asserted-by":"crossref","first-page":"adv00866","DOI":"10.2340\/actadv.v103.4556","volume":"103","author":"EM Lee","year":"2023","unstructured":"Lee EM, Cho YT, Chan TC, Shen D, Chu CY, Tang CH. Economic burden of atopic dermatitis in Taiwan. Acta Derm Venereol. 2023;103:adv00866.","journal-title":"Acta Derm Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01244-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01244-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01244-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T12:43:51Z","timestamp":1726145031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01244-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1244"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01244-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Han-Fang Liao and Sean Gardiner are employees of Pfizer. Yoko Kataoka has received lecturer honoraria from Sanofi, AbbVie, Pfizer and Maruho, and research funding from Sanofi, Leo Pharma, Pfizer, Maruho, Lilly, AbbVie, Otsuka, Taiho and Amgen. Yung Chan is a speaker for AbbVie, Bioderma, Galderma, Inova, Eli Lily, Lumenis, Menarini and Pfizer; an advisory board member for AbbVie, Bayer, Bioderma, CeraVe, Eli Lilly, Menarini, Pfizer, Sanofi, Quanta System and Janssen. Chia-Yu Chu is an investigator for AbbVie, Amgen, Dermira, Eli Lilly, Janssen, Novartis, Oneness Biotech, Pfizer, Regeneron Pharmaceuticals Inc., Roche and Sanofi; a consultant for AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche and Sanofi; a speaker for AbbVie, Eli Lilly, GlaxoSmithKline, Janssen, Mylan, Novartis, Pfizer, Roche, Sanofi and Viatris; and an advisory board member for AbbVie, Amgen, Mylan, Pfizer, Roche, Sanofi and Viatris. Nisha Suyien Chandran has received fees for participation in advisory boards from AbbVie, Johnson & Johnson, Sanofi, Pfizer, DKSH, L\u2019Oreal and Novartis; investigator fees for clinical trials from AbbVie, Novartis, Amgen, Sanofi and Boehringer Ingelheim; and speaker honoraria from Galderma, Johnson & Johnson, LEO, Pfizer, Sanofi and Lion Corporation. All other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval was received from the following IRBs: Korea University Ansan Hospital, Chulalongkorn University, Father Muller Hospital, NPO MINS, National Taiwan University Hospital, Hong Kong Doctor Union and Sir Run Run Shaw Hospital. The Parkway Independent Ethics Committee granted an exemption from review. The study was conducted in accordance with the protocol, Guidelines for Good Pharmacoepidemiology Practices, and the Declaration of Helsinki. All participants provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}